This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital malformation of musculoskeletal system, unspecified근골격계통의 상세불명의 선천기형

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q79.9 / Special Copayment Reduction: V155 / Re-certification cycle: 5 years
B. SynonymsCongenital anomaly of musculoskeletal system NOS, congenital deformity of musculoskeletal system NOS
C. Adult onsetMostly found at birth or in infancy, but mild malformations sometimes present with symptoms in adulthood
1. HistoryICD residual classification code; use of the code tends to decrease with advances in diagnostic technology
2. CausesHeterogeneous causes such as genetic abnormalities, environmental factors, and developmental abnormalities; a single cause cannot be identified
3. GeneticsPolygenic or single-gene abnormalities possible; evaluation for associated chromosomal abnormalities needed
4. EpidemiologyAll congenital musculoskeletal malformations: about 0.5~1% of live births; Q79.9 decreases as cases move to more precise codes
5. PathophysiologyAbnormalities at the embryonic stage of musculoskeletal development; defects in cell migration, differentiation, and signaling
6. SymptomsVaries by affected site; musculoskeletal deformity, pain, functional limitation, etc.
7. SignsIdentified on systematic physical examination; specific physical findings for each affected site
8. ScreeningPrenatal ultrasound and neonatal physical examination are the key screening tools
9. DiagnosisAttempt reclassification to a specific code with detailed imaging and genetic testing; Q79.9 is a diagnosis of exclusion
10. TreatmentConservative or surgical treatment of individual abnormalities; multidisciplinary approach
11. PrognosisVaries by affected site and associated malformations
12. PreventionPrenatal care, prenatal diagnosis, risk factor reduction
13. ReferencesStoll C et al. Epidemiology of congenital limb deficiencies. and 9 other papers

1. History

ICD-10 code Q79.9, Congenital malformation of musculoskeletal system, unspecified, is a residual classification code used for congenital musculoskeletal malformations that cannot be classified under another specific code (Q65~Q79.8). Synonyms include congenital anomaly of musculoskeletal system NOS and congenital deformity of musculoskeletal system NOS, where NOS (not otherwise specified) means that a more precise classification has not been made.

Classification systems for congenital musculoskeletal malformations have developed gradually since the 19th century. In the early 20th century, Swinyard, Swanson, and others proposed classification systems for limb deficiencies and dysplasias, and the Teratology Society and several specialty societies have continued to refine the classification systems. In the development of the ICD as well, the classification of congenital musculoskeletal malformations became increasingly subdivided, and when ICD-9 transitioned to ICD-10, the category of congenital musculoskeletal malformations expanded greatly. ICD-11 provides even more detailed classification, and with advances in molecular genetics, many malformations previously classified as unspecified are being reclassified into specific genetic syndromes.

The Q79.9 code is gradually being replaced by more specific codes as diagnostic technology advances. With the spread of high-resolution prenatal ultrasound, next-generation sequencing (NGS), and whole exome/genome analysis, malformations that previously could not be classified are being reclassified into specific genetic syndromes or codes. Therefore, the meaning of Q79.9 is changing to a temporary code for cases in which diagnostic evaluation is not yet complete, or a code for malformations that cannot be classified more specifically even after all tests have been completed. When the Q79.9 code is used in clinical practice, it is important to check whether further diagnostic evaluation has been carried out or is planned.

2. Causes

Given the nature of an unspecified code, the causes of cases falling under Q79.9 are very diverse and may differ for each individual patient. A review of the known causal factors across congenital musculoskeletal malformations is as follows.

Genetic factors form the most important group of causes of congenital musculoskeletal malformations. Single-gene abnormalities (Mendelian disorders) are cases in which a mutation in a specific gene directly affects musculoskeletal development, including abnormalities of collagen genes (COL family), fibroblast growth factor receptors (FGFR family), Wnt signaling-related genes, and transcription factors (PAX, HOXD families). Musculoskeletal malformations may also accompany chromosomal abnormalities (e.g., Down syndrome trisomy 21, Turner syndrome, trisomy 18). Polygenic and multifactorial inheritance also account for a considerable portion of musculoskeletal malformations, arising from the interaction of genetic predisposition and environmental factors. Among environmental factors, exposure to teratogens during pregnancy is important. Valproic acid is associated with neural tube defects and musculoskeletal malformations, and drugs such as excess vitamin A and thalidomide are also known to cause limb malformations. Hyperglycemia during pregnancy, folic acid deficiency, radiation exposure, and certain infections (rubella, cytomegalovirus, etc.) can also cause musculoskeletal malformations. Among mechanical factors, intrauterine space constraints (twins, oligohydramnios), abnormal fetal position, and uterine malformations can cause limb deformities. The typical situation in which the Q79.9 code is provisionally applied is when none of the above causes applies or the cause cannot be identified with existing tests.

3. Genetics

The genetic background of Q79.9, by definition, includes states in which no specific gene or chromosomal abnormality has been established. Clinically, however, in many patients assigned this code, the cause may be identified through additional genetic testing.

A stepwise approach is recommended for the genetic evaluation of congenital musculoskeletal malformations. As the first step, numerical chromosomal abnormalities and microdeletion/microduplication syndromes are excluded with chromosomal karyotyping or array comparative genomic hybridization (array CGH). These tests can find the cause in roughly 20~25% of multiple congenital malformations. As the second step, whole exome sequencing (WES) or a musculoskeletal malformation-related gene panel test is performed. Whole exome analysis covers about 85% of protein-coding regions, and its diagnostic yield reaches about 30~40% in musculoskeletal malformations of single-gene cause. In particular, the trio approach, which analyzes the parents and the affected child simultaneously, is advantageous for identifying de novo mutations. If a pathogenic variant is identified on genetic testing, the case should be reclassified into a more specific ICD code matching the syndrome, and subtype-specific clinical management guidelines should be applied. If a variant of uncertain significance (VUS) is detected, parental testing and additional functional studies are considered, and the correlation with the clinical phenotype is reassessed. If genetic testing also fails to find the cause, whole genome sequencing (WGS) can be used as a last resort.

4. General epidemiology

Congenital musculoskeletal malformations as a whole are a high-frequency category of congenital malformations, estimated to occur in about 0.5~1% of live births. Musculoskeletal malformations are the most common category of congenital malformations after cardiac and nervous system malformations and are a major cause of long-term functional impairment and reduced quality of life. Epidemiologic data on the Q79.9 code itself are limited, and because this code is used as a provisional code or a residual code after exclusion, estimating the actual prevalence is difficult.

According to birth defect surveillance studies, the proportion accounted for by Q79.9 within the entire Q79 category (abdominal wall and other musculoskeletal malformations) varies with the health care system and level of diagnosis. In resource-rich medical settings, access to genetic testing and detailed imaging is high, so the proportion classified as Q79.9 is low; conversely, in settings with limited diagnostic infrastructure, the proportion of unspecified classifications is high. By age, Q79.9 diagnoses are concentrated in the neonatal period or infancy and are often changed to more specific codes as diagnostic evaluation proceeds. Sex distribution varies by individual condition; across congenital musculoskeletal malformations, some are more common in males and some more common in females. Korean data in the Asian region are gradually accumulating through the national congenital malformation registry program and the health insurance database.

5. Pathophysiology

Congenital malformations of the musculoskeletal system arise from abnormalities at each stage of embryonic musculoskeletal development. Understanding the normal developmental process is the basis for grasping the mechanisms of malformation.

Musculoskeletal development begins about 4 weeks after fertilization. The spine and limbs are formed through segmentation, migration, and differentiation of cells of mesodermal origin. Somite development is central to the formation of the spine and skeletal muscle, and muscles are formed as myoblasts differentiate from the dermomyotome of the somites. Limb development begins with the appearance of the limb bud, and proximodistal, dorsoventral, and anteroposterior patterning is determined by molecular signals (FGF, Sonic Hedgehog, Wnt, etc.) from the apical ectodermal ridge (AER) and the zone of polarizing activity (ZPA). Tendon development is coordinated by muscle-skeleton interaction signals, and transcription factors such as Scleraxis (Scx) and tenomodulin are involved in the differentiation of tendon progenitor cells. If genetic abnormalities, teratogens, or mechanical factors act at any stage of this developmental process, musculoskeletal malformations can occur. In Q79.9, the developmental stage at which the abnormality occurred has not been identified by current tests, so it is helpful to estimate the timing of development based on the clinical phenotype. For example, limb reduction defects may suggest an abnormality at the limb development stage (4~8 weeks of gestation), and joint contractures an abnormality at the stage of muscle and tendon maturation (after 10 weeks of gestation).

6. Symptoms

The symptoms of patients classified as Q79.9 vary greatly depending on the musculoskeletal structures affected and their extent. Because of the nature of an unspecified code, there is no single symptom profile, so this section comprehensively describes the symptom groups that can commonly appear in congenital musculoskeletal malformations.

Morphological abnormalities are the most obvious symptom; external malformations of the limbs or trunk are found at birth or in infancy. In mild cases, medical staff or parents may not notice at first, and they are found incidentally at pediatric health checkups or on tests done for other reasons. Functional limitations may include reduced joint range of motion, muscle weakness, gait abnormalities, and reduced fine hand motor function. During growth, joint contractures may worsen or, conversely, improve with physical therapy and growth. Pain varies by affected site; in particular, when there is an inadequately corrected deformity, pain from joint overload develops during growth or in adulthood. Neurological symptoms may be present; in particular, when spinal deformity is present, radiating pain, sensory abnormalities, and muscle weakness due to spinal cord or nerve root compression can appear. Psychological problems such as social withdrawal, low self-esteem, depression, and anxiety due to external malformations may accompany the condition from childhood to adulthood. Symptom severity ranges from mild differences in appearance to severe functional impairment depending on the extent of involvement, symmetry, and presence of associated malformations.

7. Signs

The clinical signs of Q79.9 differ depending on the affected site and the characteristics of the specific malformation. Identifying and recording abnormalities through a systematic physical examination is essential for diagnosis and follow-up.

In general observation, overall asymmetry of body shape, postural abnormalities, limb length discrepancy, and the like are checked. Inspection proceeds stepwise from the proximal to the distal limbs, evaluating muscle development, joint appearance, and skin changes together. In the joint examination, the active and passive range of motion of each joint is measured with a goniometer or standardized tests and recorded. Contracture, hypermobility, tendency to dislocation, and the like are checked. In the muscle examination, the bulk, tone, and strength (Medical Research Council grade) of each muscle group are evaluated. When there is unilateral muscle atrophy or absence of a muscle, the degree of asymmetry is quantified by comparison with the opposite side. In the spine examination, spinal abnormalities such as lordosis, kyphosis, and scoliosis are evaluated with tests such as the Adam forward bend test. When complex congenital malformations are present, associated abnormalities of the chest, abdomen, and head and neck are also examined. On skin examination, pigmentary abnormalities, vascular malformations, subcutaneous nodules, and the like can be clues to specific genetic syndromes and should be observed carefully.

8. Screening

Screening for congenital musculoskeletal malformations can be divided into the prenatal and neonatal stages, and early detection leads directly to early therapeutic intervention and prevention of complications.

Prenatal ultrasound is the most important screening tool. At the first detailed ultrasound at 11~14 weeks of gestation and the second detailed ultrasound at 18~22 weeks, the fetal musculoskeletal structures, such as the limbs, spine, and chest wall, are systematically evaluated. Limb length measurements (lengths of the humerus, radius, ulna, femur, tibia, and fibula), limb shape, joint mobility (observation of fetal movement), and trunk symmetry are checked. When an abnormality is suspected, fetal MRI provides additional information. Noninvasive prenatal testing (NIPT) is useful for screening numerical chromosomal abnormalities and some microdeletion syndromes, but its use for screening most single-gene musculoskeletal malformations is limited. A neonatal physical examination should be performed in all neonates within 24 hours after birth and includes limb shape, joint range of motion, muscle tone, and palpation of the spine. If an abnormality is found at this time, additional imaging such as musculoskeletal ultrasound and X-rays is performed immediately. In high-risk groups (family history, other congenital malformations, associated chromosomal abnormalities), early referral to a specialized genetics clinic is recommended. In infancy and the preschool years, attainment of developmental (motor) milestones is evaluated at regular health checkups, and additional musculoskeletal evaluation is performed if delay is suspected.

9. Diagnosis

Q79.9 is a diagnosis-of-exclusion code assigned when no suitable code exists after all other congenital musculoskeletal malformation codes have been reviewed. Therefore, efforts to identify and classify the malformation as specifically as possible must come first in the diagnostic process.

The first step in diagnostic evaluation is detailed collection of clinical information, taking a detailed history of family history (a three-generation pedigree), pregnancy history (risk factors such as drugs, infection, radiation exposure, diabetes), and the perinatal course. For imaging, depending on the affected site, X-rays (evaluation of skeletal abnormalities), musculoskeletal ultrasound (evaluation of muscle and tendon abnormalities, preferred in neonates and infants), and MRI (evaluation of associated soft tissue and neural structures) are used. A whole-body skeletal X-ray survey (skeletal survey) is performed when multiple skeletal abnormalities are suspected. Genetic testing is central to identifying the cause of undiagnosed musculoskeletal malformations. Array CGH or SNP array is useful for detecting microdeletions/duplications and uniparental disomy. Whole exome analysis (WES) or musculoskeletal malformation-related gene panels are used to identify single-gene causes. As biochemical tests, serum alkaline phosphatase, calcium, phosphorus, and urine mucopolysaccharide analysis may be needed to differentiate some metabolic bone diseases (hypophosphatasia, mucopolysaccharidosis, etc.). If the cause is identified through these tests, the case is reclassified into the specific ICD code for that disease, and Q79.9 is kept as the final code only when the cause remains unknown.

10. Treatment

Treatment of patients classified as Q79.9 is individualized according to the characteristics of the specifically identified malformation, extent of involvement, functional impact, and the patient's age. When a specific genetic syndrome is diagnosed, the treatment guidelines for that syndrome are followed, and even when the cause is unknown, treatment is planned according to the functional and morphological characteristics of the malformation.

When conservative treatment is possible, physical therapy, occupational therapy, and orthoses take priority. For joint contractures, conservative approaches such as serial casting, night splints, and continuous passive motion (CPM) are tried first. For joint instability, muscle strengthening exercises and custom orthoses are the key treatments. When there is limb length discrepancy, function is supplemented with assistive devices (compensatory shoes, orthoses), and limb lengthening surgery is considered if needed. Surgical treatment is applied to joint contractures that do not respond to conservative treatment, functional limb malformations, correction of spinal deformities, and the like. The timing of surgery is decided considering the stage of growth and development, and consultation with a pediatric orthopedic surgeon is needed. When complex reconstructive surgery is needed, a multidisciplinary team approach involving hand surgery, plastic surgery, and orthopedics is recommended. Rehabilitation is essential for functional recovery after surgery and adaptation to daily life, and a comprehensive rehabilitation program involving occupational therapists, physical therapists, speech therapists (when orofacial muscle malformations are present), psychologists, and others is ideal. In adulthood as well, continued follow-up is needed to maintain function and prevent complications (early arthrosis, etc.).

11. Prognosis

The prognosis of Q79.9 varies greatly depending on the characteristics of the affected musculoskeletal structures, the severity of the malformation, the presence of associated malformations, and whether early therapeutic intervention is given. With a single malformation and mild functional limitation, near-normal function and quality of life can be expected with appropriate treatment and rehabilitation.

When there are multiple malformations or extensive musculoskeletal abnormalities of unknown cause, the prognosis is more complex. In particular, when chromosomal abnormalities or severe genetic syndromes are present, the prognosis may be complex due to intellectual disability, multiple organ abnormalities, repeated surgery, and so on. If a more specific classification is made during diagnostic evaluation, accurate information should be provided to the patient and caregivers with reference to the natural course and prognosis of that disease. According to long-term follow-up studies, many patients with congenital musculoskeletal malformations need physical therapy, orthoses, or additional surgery even in adulthood and experience chronic pain and psychosocial problems. Focusing early on optimizing function and preventing complications through a multidisciplinary approach is key to improving the long-term prognosis. When surgical treatment is needed, a long-term treatment plan should be established aiming at the final result after growth is complete (skeletal maturity outcome).

12. Prevention

Because the cause of unspecified congenital malformations of the musculoskeletal system is often unclear, specific preventive measures are limited. However, reducing known risk factors for musculoskeletal malformations and starting early treatment through early detection are the most realistic prevention strategies.

Preconception care includes securing adequate nutritional status (especially taking folic acid 0.4~5mg/day from before pregnancy), controlling underlying diseases (diabetes, thyroid disease, etc.), and careful prescribing of teratogenic drugs in women of childbearing age. Known teratogens such as valproic acid, retinoids (vitamin A derivatives), and methotrexate should in principle be prohibited or strictly restricted in women of childbearing age and pregnant women. Care during pregnancy includes completely avoiding alcohol, smoking, and illicit drug use, receiving regular prenatal checkups, and identifying fetal abnormalities early with prenatal ultrasound. Infection prevention (rubella vaccination, adherence to food safety rules, etc.) is also important. Genetic counseling should be provided to parents who have previously had a child with a musculoskeletal malformation, when there is a family history of musculoskeletal malformations, and when a specific genetic syndrome is suspected, discussing recurrence risk and prenatal diagnosis options. Strengthening the newborn screening system and building a system for prompt referral to specialized medical institutions when abnormalities are found are prevention strategies at the societal level. In the long term, as genomic research and congenital malformation registry programs expand, identification of causes is expected to improve, allowing more accurate diagnosis and prevention strategies for patients currently classified as Q79.9.

13. References

  1. Stoll C, Alembik Y, Dott B, Roth MP. Epidemiology of congenital limb deficiencies. Ann Genet. 1992;35(3):168-175. PMID:1489973
  2. Winter RM, Baraister M. London Dysmorphology Database. Oxford University Press; 2001. ISBN:9780192630483
  3. Stevenson RE, Hall JG. Human Malformations and Related Anomalies. 2nd ed. Oxford University Press; 2006. ISBN:9780195178425
  4. Baujat G, Le Merrer M. Ellis van Creveld syndrome. Orphanet J Rare Dis. 2007;2:27. PMID:17547743
  5. Greenberg CR, Rimoin DL. Prenatal diagnosis of musculoskeletal disorders. Prenat Diagn. 1985;5(6):433-440. PMID:4070600
  6. Orioli IM, Castilla EE, Barbosa-Neto JG. The birth prevalence rates for the skeletal dysplasias. J Med Genet. 1986;23(4):328-332. PMID:3735449
  7. Spranger JW, Brill PW, Nishimura G, et al. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3rd ed. Oxford University Press; 2012. ISBN:9780195396089
  8. Bamshad M, Van Heest AE, Pleasure D. Arthrogryposis: a review and update. J Bone Joint Surg Am. 2009;91 Suppl 4:40-46. PMID:19571066
  9. Hall JG. Arthrogryposis multiplex congenita: etiology, genetics, classification, diagnostic approach, and general aspects. J Pediatr Orthop B. 1997;6(3):159-166. PMID:9260643
  10. Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 1997;89(5):773-779. PMID:9182764